Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics has received FDA approval to initiate a Phase I clinical study for its first-in-class radiopharmaceutical, Betabart (RV-01), targeting the B7-H3 immune checkpoint molecule in solid tumors. This approval marks a significant milestone for the company and its joint venture with MD Anderson Cancer Center, as RV-01 has shown promise in preclinical studies by effectively targeting tumors with minimal adverse effects, potentially offering a novel treatment strategy for aggressive cancers.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need. The company is listed on ASX and NASDAQ and has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer.
Average Trading Volume: 2,215,769
Technical Sentiment Signal: Sell
Current Market Cap: A$54.39M
See more data about RAD stock on TipRanks’ Stock Analysis page.